SCHEMBL20890076

SCHEMBL20890076

CNC1CCc2ccc(C(C)C)cc2C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 4/20 0.43
DRD3 P35462 4/20 0.43
DRD4 P21917 2/20 0.43
CA1 P00915 4/20 0.40
CA2 P00918 4/20 0.40
ACHE P22303 4/20 0.40
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40
MEN1 O00255 2/20 0.38
CYP3A4 P08684 2/20 0.38
KMT2A Q03164 2/20 0.38
KARS1 Q15046 2/20 0.38
TSHR P16473 2/20 0.38
PDK1 Q15118 1/20 0.38
PDK2 Q15119 1/20 0.38
PDK3 Q15120 1/20 0.38
PDK4 Q16654 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20884971 0.94 DRD2 (0.43) DRD2DRD3DRD4CA1CA2
SCHEMBL20884970 0.86 CHRNB2 (0.39) CA1CA2MEN1CYP3A4KMT2A
SCHEMBL20883969 0.84 DRD3 (0.39) DRD2DRD3DRD4CA1CA2
SCHEMBL20883863 0.81 CA1 (0.49) DRD2DRD3CA1CA2ACHE
SCHEMBL20883884 0.81 MTNR1A (0.64) CA1CA2ACHEMTNR1AMTNR1B
SCHEMBL4795630 0.80 ACHE (0.43) DRD2DRD3DRD4CA1CA2
SCHEMBL20909683 0.78 DRD3 (0.46) DRD2DRD3DRD4CA1CA2
SCHEMBL26298480 0.77 HTR1D (0.45) DRD2DRD3DRD4CA1CA2
SCHEMBL12376490 0.77 KARS1 (0.42) DRD2DRD3DRD4MEN1CYP3A4
SCHEMBL10560019 0.77 CYP3A4 (0.39) DRD2DRD3DRD4MEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190106427-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2019-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190106427-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF WEE1, WEE2, NME1 DRD2 4370/4885DRD3 4178/4885DRD4 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.